These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 24074794

  • 1. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S.
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [Abstract] [Full Text] [Related]

  • 2. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS.
    Cancer J; 2015 Aug; 21(4):274-83. PubMed ID: 26222079
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role of angiogenesis inhibition in the treatment of breast cancer.
    Sledge GW, Rugo HS, Burstein HJ.
    Clin Adv Hematol Oncol; 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PubMed ID: 17139244
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
    Paez-Ribes M, Man S, Xu P, Kerbel RS.
    PLoS One; 2016 Oct; 11(6):e0158034. PubMed ID: 27355476
    [Abstract] [Full Text] [Related]

  • 9. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
    Man S, Munoz R, Kerbel RS.
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
    [Abstract] [Full Text] [Related]

  • 10. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
    Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G, Kerbel RS.
    Sci Transl Med; 2015 Apr 08; 7(282):282ra50. PubMed ID: 25855496
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J.
    Lancet Oncol; 2014 Oct 08; 15(11):1269-78. PubMed ID: 25273342
    [Abstract] [Full Text] [Related]

  • 12. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS.
    Cancer Res; 2006 Apr 01; 66(7):3386-91. PubMed ID: 16585158
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E.
    Cancer Res; 2002 Oct 15; 62(20):5727-35. PubMed ID: 12384531
    [Abstract] [Full Text] [Related]

  • 14. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E, Yin M, Peters CG, Lee CR, Brown D, Xu P, Man S, Jayaraman L, Rohde E, Chow A, Lazarus D, Eliasof S, Foster FS, Kerbel RS.
    Cancer Res; 2016 Aug 01; 76(15):4493-503. PubMed ID: 27325647
    [Abstract] [Full Text] [Related]

  • 15. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA.
    Oncologist; 2004 Aug 01; 9(5):518-27. PubMed ID: 15477636
    [Abstract] [Full Text] [Related]

  • 16. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA.
    Clin Breast Cancer; 2000 Apr 01; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [Abstract] [Full Text] [Related]

  • 17. Targeting angiogenesis in metastatic breast cancer.
    Reddy S, Raffin M, Kaklamani V.
    Oncologist; 2012 Apr 01; 17(8):1014-26. PubMed ID: 22843553
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E, Xu P, Chow A, Man S, Hilberg F, Kerbel RS.
    J Exp Clin Cancer Res; 2019 Jan 11; 38(1):16. PubMed ID: 30635009
    [Abstract] [Full Text] [Related]

  • 19. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.
    Lancet Oncol; 2015 Jul 11; 16(7):816-29. PubMed ID: 26092818
    [Abstract] [Full Text] [Related]

  • 20. Angiogenesis as targeted breast cancer therapy.
    Hayes DF, Miller K, Sledge G.
    Breast; 2007 Dec 11; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.